LOS ANGELES, CA--(Marketwired - Apr 11, 2013) - MyMedicalRecords, Inc. ("MMR"), a wholly owned subsidiary of MMRGlobal, Inc. (
According to the complaint, Quest offers a product known as Gazelle. Gazelle is a mobile health application that is a PHR. Gazelle allows a customer to receive and store through his or her cell phone medical information, including personal medical records. Gazelle is configured to allow Quest to send lab results and other information directly to the customer's account that the customer may access through his or her cell phone. On information and belief, while access is allowed via a cell phone, the personal health information is stored on servers by Quest. The complaint also alleges that on information and belief, Quest, through Gazelle or other products, enables physicians using Quest's Care360 product to also share information directly with patients. Quest's Care360, an EHR platform, provides clinical connectivity and electronic healthcare solutions to healthcare institutions, physicians and patients. Customers using Gazelle can also receive records directly from healthcare providers using Care360, through the Care360 system, and those healthcare providers that are not using Quest's Care360 product.
Additionally, customers are asked to set up a Quest Diagnostic Patient Account, creating a user name and password specific for that account to provide access and security. Through Gazelle and the Quest Diagnostic Patient Account, customers may electronically share, including by email and fax, their healthcare information with physicians, pharmacists and anyone else they choose. Customers can also enter and record a variety of personal health information into Gazelle and the Quest Diagnostic Patient Account. Gazelle allows patients to receive lab results directly from Quest, as well as to see, store and share prescriptions, physician information, immunizations, emergency contacts, medical conditions, and allergies. The number of different physicians whose records can be included in Quest's personal health record is not limited. Further, the physicians need not be part of the same physician group or practice at the same hospital. The personal health records stored as part of Quest's patient portal is independent from records stored by the physician or healthcare provider.
Working with Liner Grode Stein Yankelevitz Sunshine Regenstreif & Taylor LLP, MMR has been pursuing efforts to monetize its patent portfolio and other IP by investigating potential infringement of MMR's patents by entities such as retail pharmacies, EHR and PHR vendors, laboratory systems, hospitals, physicians, and other healthcare professionals.
For additional information regarding the MyMedicalRecords, Inc. complaint against Quest Diagnostics, Inc., contact Ted Ward at Liner Grode Stein Yankelevitz Sunshine Regenstreif & Taylor LLP at (310) 500-3384.
About MMRGlobal MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc., provides secure and easy-to-use online Personal Health Records ("PHRs") and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, retail pharmacies, and professional organizations and affinity groups. The MyMedicalRecords PHR enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. MyMedicalRecords is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user's account. The Company's professional offering, MMRPro , is designed to give physicians' offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients through an integrated patient portal. Through its merger with Favrille, Inc. in January 2009, the Company acquired intellectual property biotech assets that include anti-CD20 antibodies and data and samples from its FavId™/Specifid™ vaccine clinical trials for the treatment of B-Cell Non-Hodgkin's lymphoma. To learn more about MMRGlobal, Inc. visit www.mmrglobal.com . View demos and video tutorials of the Company's products and services at www.mmrtheater.com .
Forward-Looking Statements All statements in this press release that are not strictly historical in nature, including, without limitation, intellectual property enforcement actions, infringement claims or litigation, intellectual property licenses, and future performance, management's expectations, beliefs, intentions, estimates or projections, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Some can be identified by the use of words (and their derivations) such as "need," "possibility," "potential," "intend," "offer," "development," "if," "negotiate," "when," "begun," "believe," "achieve," "will," "estimate," "expect," "maintain," "plan," and "continue," or the negative of these words. Actual outcomes and results of operations and the timing of selected events may differ materially from the results predicted, and any reported results should not be considered as an indication of future performance. Such statements are necessarily based on assumptions and estimates and are subject to various risks and uncertainties, including those relating to the possible invalidity of the underlying assumptions and estimates and possible changes or developments in economic, business, industry, market, legal and regulatory circumstances and conditions and actions taken or omitted to be taken by third parties, including customers, suppliers, business partners, potential licensees, competitors and legislative, judicial and other governmental authorities and officials. Factors that could cause or contribute to such differences include, but are not limited to: unexpected outcomes with respect to intellectual property enforcement actions, claims of intellectual property infringement and general intellectual property litigation; our ability to maintain, develop, monetize and protect our patent portfolio for both the Company's health IT and biotechnology intellectual property assets in the U.S. and internationally; research and valuation reports on the Company; the timing of milestone payments in connection with licensing our intellectual property; our ability to establish and maintain strategic relationships; changes in our relationships with our licensees; the risk the Company's products are not adopted or viewed favorably by the healthcare community and consumer retail market; business prospects, results of operations or financial condition; risks related to the current uncertainty and instability in financial and lending markets, including global economic uncertainties; the timing and volume of sales and installations; the length of sales cycles and the installation process; the market's acceptance of new product and service introductions; competitive product offerings and promotions; changes in government laws and regulations including the 2009 HITECH Act and changes in Meaningful Use and the 2010 Affordable Care Act; future changes in tax legislation and initiatives in the healthcare industry; undetected errors in our products; the possibility of interruption at our data centers; risks related to third party vendors; risks related to obtaining and integrating third-party licensed technology; risks related to a security breach by third parties; risks associated with recruitment and retention of key personnel; other litigation matters; uncertainties associated with doing business internationally across borders and territories; and additional risks discussed in the Company's filings with the Securities and Exchange Commission. The Company is providing this information as of the date of this release and, except as required by applicable law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.
CONTACT: Michael Selsman Public Communications Co. ms@publiccommunications.biz (310) 922-7033
